Moody Aldrich Partners LLC Sells 60,990 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Moody Aldrich Partners LLC lowered its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 22.0% in the 4th quarter, HoldingsChannel reports. The firm owned 215,657 shares of the biopharmaceutical company’s stock after selling 60,990 shares during the quarter. Moody Aldrich Partners LLC’s holdings in Catalyst Pharmaceuticals were worth $4,501,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. Jane Street Group LLC lifted its holdings in Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after buying an additional 285,564 shares during the period. Walleye Capital LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter valued at about $4,936,000. AQR Capital Management LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 87.1% in the 2nd quarter. AQR Capital Management LLC now owns 488,386 shares of the biopharmaceutical company’s stock valued at $7,565,000 after buying an additional 227,321 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Catalyst Pharmaceuticals by 146.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock worth $7,285,000 after buying an additional 217,956 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its stake in shares of Catalyst Pharmaceuticals by 47.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 618,296 shares of the biopharmaceutical company’s stock worth $9,577,000 after acquiring an additional 200,370 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $22.84 on Wednesday. The stock has a 50 day simple moving average of $21.86 and a 200-day simple moving average of $20.61. Catalyst Pharmaceuticals, Inc. has a 1-year low of $13.12 and a 1-year high of $24.27. The company has a market cap of $2.72 billion, a price-to-earnings ratio of 19.36, a PEG ratio of 2.28 and a beta of 0.79.

Analyst Ratings Changes

Several analysts have recently commented on CPRX shares. Bank of America reiterated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. StockNews.com cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. HC Wainwright raised their price target on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Stephens began coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, Truist Financial raised their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $32.86.

Insiders Place Their Bets

In other news, Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Steve Miller sold 50,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares of the company’s stock, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 79,500 shares of company stock worth $1,754,140. Corporate insiders own 11.00% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.